Dr Kiran Mazumdar, CMD, Biocon (Photo Courtesy: www.bbc.co.uk)
The partnership has a strong portfolio of generic insulin analogs and biosimilars including Monoclonal Antibodies (MAbs) and recombinant proteins at various stages of development.
Two molecules Pegfilgrastim (PEG-G-CSF) and Adalimumab have entered global Phase-3 clinical trials. While the PEG-G-CSF trial is well underway the Adalimumab trial has been recently initiated, said the company in a statement.
In addition, the Phase-3 global clinical trial for Trastuzumab is progressing in more than 100 sites around the world. An initial ROW focused Phase-3 trial for Bevacizumab is also underway, said Biocon.
Generic Insulin Analogs